News

2018

Nexstim Plc – first NBT® system for depression ordered in the US

22 May 2018

iSTAR Medical’s MINIject delivers exceptional 6-month results

15 May 2018

Sequana Medical announces publication of results of multicentre randomized controlled study

19 March 2018

Mainstay Medical announces € 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization

15 February 2018

2017

Confo Therapeutics enters into drug discovery collaboration with Roche

19 December 2017

Mainstay Medical announces positive outcome of interim analysis

11 December 2017

Nexstim Plc appoints Steve Beller as Vice President and General Manager

1 December 2017

Sequana Medical announces results of the MOSAIC trial data presented at 2017 AASLD

24 October 2017

iSTAR Medical completes enrolment of first-in-human MIGS trial

17 October 2017

Sequana Medical announces publication of results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T).

4 October 2017

Confo Therapeutics enters into drug discovery collaboration with Lundbeck

26 September 2017

Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA

27 June 2017

• 1
• ...
• 3
• 4
• 5
• 6